Sequenom's Shares Rise on Genotyping Test Launch | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Sequenom were up around 7 percent at $4.36 in mid-afternoon trade on the Nasdaq, after the firm announced the launch of its SensiGene Fetal RHD Genotyping test.

The test will be offered through Sequenom's CAP-credited and CLIA-certified lab, the Sequenom Center for Molecular Medicine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.